

LITERATUR

10.1 SCHIZOPHRENEN

Terminologie

- Bleuler E (1911). *Dementia praecox oder Gruppe der Schizophrenien*. Wien, Leipzig: Deuticke.
- Griesinger W (1845). Die Pathologie und Therapie der psychischen Krankheiten. Stuttgart: Krabbe.
- Hecker E (1871). Die Hebephrenie. Ein Beitrag zur klinischen Psychopathologie. *Virchows Arch* 52: 394–429.
- Kahlbaum K (1874). Die Katatonie oder das Spannungssirresein. Berlin: Hirschwald.
- Kraepelin E (1893). *Psychiatrie*. 4. A. Leipzig: Abel (Meixner).
- Schneider K (1992). *Klinische Psychopathologie*. 14. A. Stuttgart, New York: Thieme.
- Wing JK, Cooper JE, Sartorius N (1974). *Measurement and Classification of Psychiatric Symptoms*. Cambridge: Cambridge University Press.
- Epidemiologie*
- Aleman A, Kahn RS, Selten JP (2003). Sex differences in the risk of schizophrenia: evidence from meta-analysis. *Arch Gen Psychiatry* 60(6): 565–571.
- Böök JA (1953). A genetic and neuropsychiatric investigation of a North-Swedish population (with special regard to schizophrenia and mental deficiency). *Acta Genetica* 4: 1–100.
- Böök JA, Wetterberg L, Modrzenska K (1978). Schizophrenia in a North-Swedish geographical isolate, 1900–1977: epidemiology, genetics and biochemistry. *Clin Genet* 14: 373–394.
- Crocetti GM, Lemkau PV, Kulcar Z, Kesic B (1971). Selected aspects of the epidemiology of psychoses in Croatia, Yugoslavia II. The cluster sample and the results of the pilot survey. *Am J Epidemiol* 94: 126–134.
- Galletly C, Castle D, Dark F, et al. (2016). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. *Aust N Z J Psychiatry* 50(5): 410–472.
- Jablensky A, Sartorius N, Ernberg G, et al. (1992). Schizophrenia: Manifestations, Incidence and Course in Different Cultures. A World Health Organization ten-country study. *Psychol Med (Monograph Suppl 20)*. Cambridge: Cambridge University Press.
- Jablensky A (1995). Schizophrenia: the epidemiological horizon. In: Hirsch SR, Weinberger DR (eds.). *Schizophrenia*. Oxford: Blackwell, pp. 206–252.
- Ksir C, Hart CL (2016). Cannabis and psychosis: a critical overview of the relationship. *Curr Psychiatry Rep* 18(2): 12.
- Leucht S, Burkard T, Henderson J, Maj M, Sartorius N (2007). Physical illness and schizophrenia: a review of the literature. *Acta Psychiatr Scand* 116(5): 317–333.
- Maglione JE, Thomas SE, Jeste DV (2014). Late-onset schizophrenia: do recent studies support categorizing LOS as a subtype of schizophrenia? *Curr Opin Psychiatry* 27(3): 173–178.
- Marconi A, di Forti M, Lewis CM, Murray RM, Vassos E (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. *Schizophr Bull* 42(5): 1262–1269.
- McGrath J, Saha S, Chant D, Welham J (2008). Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiol Rev* 30: 67–76.
- Murray RM, Di Forti M (2016). Cannabis and psychosis: What degree of proof do we require? *Biol Psychiatry* 79(7): 514–515.
- Olfson M, Gerhard T, Huang C, et al. (2015). Premature mortality among adults with schizophrenia in the United States. *JAMA Psychiatry* 72(12): 1172–1181.
- Palmer BA, Pankratz VS, Bostwick JM (2005). The lifetime risk of suicide in schizophrenia: a reexamination. *Arch Gen Psychiatry* 62(3): 247–253.
- Schmitt A, Malchow B, Hasan A, Falkai P (2014). The impact of environmental factors in severe psychiatric disorders. *Front Neurosci* 8: 19.
- Schoeler T, Petros N, Di Forti M, et al. (2016). Association between continued cannabis use and risk of relapse in first-episode psychosis: a quasi-experimental investigation within an observational study. *JAMA Psychiatry* 73(11): 1173–1179.

- Tandon R, Keshavan MS, Nasrallah HA (2008a). Schizophrenia, "Just the Facts": What we know in 2008: part 1: Overview. *Schizophr Res* 100(1–3): 4–19.
- Tandon R, Keshavan MS, Nasrallah HA (2008b). Schizophrenia, "Just the Facts": What we know in 2008: part 2: Epidemiology and etiology. *Schizophr Res* 102(1–3): 1–18.
- Wing JK, Cooper JE, Sartorius N (1974). *Measurement and Classification of Psychiatric Symptoms*. Cambridge: Cambridge University Press.
- Symptomatik*
- Andreasen NC (1987). The diagnosis of schizophrenia. *Schizophr Bull* 13: 9–22.
- Barz H (1981). *Psychopathologie und ihre psychologischen Grundlagen*. Göttingen, Bern, Toronto: Huber.
- Bleuler E (1911). *Dementia praecox oder Gruppe der Schizophrenien*. Leipzig, Wien: Deuticke.
- Conrad K (1992). *Die beginnende Schizophrenie*. 6. A. Stuttgart, New York: Thieme.
- Creer C, Wing JU (1975). Living with a schizophrenic patient. *Br J Hosp Med* 14: 73–82.
- Cutting J (1995). Descriptive psychopathology. In: Hirsch SR, DR Weinberger (eds.). *Schizophrenia*. Oxford: Blackwell, pp. 15–27.
- Huber G (1994). *Psychiatrie*. Stuttgart: Schattauer.
- Mundt Ch (1995). Schizophrenie. In: Faust V (Hrsg.). *Psychiatrie*. Stuttgart, Jena, New York: Fischer, S. 93–109.
- Olbrich HM (1987). Ereigniskorrelierte Hirnpotenziale und Psychopathologie. *Nervenarzt* 58: 471–480.
- Olbrich HM, Maes H, Valerius G, et al. (2005). Event-related potential correlates selectively reflect cognitive dysfunction in schizophrenics. *Neural Transm* 112: 283–295.
- Scharfetter Ch (1991). *Allgemeine Psychopathologie*. Stuttgart, New York: Thieme.
- Schneider K (1992). *Klinische Psychopathologie*. 14. A. Stuttgart, New York: Thieme.
- WHO – World Health Organization (1973). *Report of the International Pilot Study of Schizophrenia*. Vol. 1. Geneva: World Health Organization.
- Subtypisierung der Schizophrenie*
- Crow TJ (1980). The molecular pathology of schizophrenia. More than one disease process. *BMJ* 280: 66–68.
- Gaebel W (2012). Status of psychotic disorders in ICD-11. *Schizophr Bull* 38(5): 895–898.
- Liddle PF (1995). Inner connections with domain of dementia praecox: role of supervisory mental processes in schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 245: 210–215.
- Ätiologie und Pathogenese: Genetik*
- Gottesman II, Shields J (1976). A critical review of recent adoption, twin and family studies of schizophrenia: behavioral genetics perspectives. *Schizophr Bull* 2: 360–401.
- Pardiñas AF, Holmans P, Pocklington AJ, et al. (2018). Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat Genet* 50(3): 381–389.
- PGC – Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014). Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511(7510): 421–427.
- Propping P (1989). *Psychiatrische Genetik. Befunde und Konzepte*. Berlin, Heidelberg, New York: Springer.
- Ripke S, O'Dushlaine C, Chambert K, et al. (2013). Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nat Genet* 45(10): 1150–1159.
- Sullivan PF, Kendler KS, Neale MC (2003). Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry* 60(12): 1187–1192.
- WHO – World Health Organization (1973). *Report of the International Pilot Study of Schizophrenia*. Vol. 1. Geneva: World Health Organization.
- Ätiologie und Pathogenese: Neurochemie und Neuropharmakologie*
- Carlsson A (1978). Antipsychotic drugs, neurotransmitters and schizophrenia. *Am J Psychiatry* 135: 164–173.

362.e2 10 Schizophrenien und andere psychotische Störungen

- Farde L, Wiesel FA, Stone-Elander S, et al. (1990). D₂-dopamine receptors in neuroleptic-naïve schizophrenic patients: a positron emission tomography study with [¹¹C] raclopride. *Arch Gen Psychiatry* 47: 213–219.
- Hasan A, Malchow B, Falkai P, Schmitt A (2014). Die Glutamathypothese der Schizophrenie. *Fortschr Neurol Psychiatr* 82: 447–456.
- Howes OD, McGuire PK, Kapur S (2008). Understanding pathophysiology is crucial in linking clinical staging to targeted therapeutics. *World Psychiatry*. Oct;7(3):162-3.
- Howes OD, Kambeitz J, Kim E, et al. (2012). The nature of dopamine dysfunction in schizophrenia and what this means for treatment. *Arch Gen Psychiatry* 69(8): 776–786.
- Howes O, McCutcheon R, Stone J (2015). Glutamate and dopamine in schizophrenia: an update for the 21st century. *J Psychopharmacol* 29(2): 97–115.
- Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D (2012). Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. *Schizophr Bull* 38(5): 958–966.
- Osmond H, Smythies J (1952). Schizophrenia: new approach. *J Mental Sci* 98: 309–322.
- PGC – Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014). Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511(7510): 421–427.
- Seeman P, Tedesco JL, Lee T, et al. (1978). Dopamine receptors in the central nervous system. *Fed Proc* 37: 130–136.
- Seeman P, Guan H, van Tol H (1993). Dopamine d4 receptors elevated in schizophrenia. *Nature* 365(6445): 441–445.
- Snyder SH, Banerjee SP, Yamamura HI, Greenberg D (1974). Drugs, neurotransmitters and schizophrenia: phenothiazines, amphetamines and enzymes synthesizing psychotomimetic drugs aid schizophrenia research. *Science* 184: 1243–1253.
- Wong DF, Wagner Jr HN, Tune E (1986). Positron emission tomography reveals elevated D₂-receptor in drug-naïve schizophrenics. *Science* 234: 1558–1563.
- Ätiologie und Pathogenese: Morphologische Befunde und andere organische Faktoren
- Brugge SP, Howes OD (2017). Heterogeneity and homogeneity of regional brain structure in schizophrenia: a meta-analysis. *JAMA Psychiatry* 74(11): 1104–1111.
- Cannon TD, van Erp TG, Rosso IM, et al. (2002). Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings and controls. *Arch Gen Psychiatry* 59: 35–41.
- Dong D, Wang Y, Chang X, et al. (2018). Dysfunction of large-scale brain networks in schizophrenia: a meta-analysis of resting-state functional connectivity. *Schizophr Bull* 44(1): 168–181.
- Dwyer DB, Falkai P, Koutsouleris N (2018). Machine learning approaches for clinical psychology and psychiatry. *Annu Rev Clin Psychol* 14: 91–118.
- Falkai P, Rossner MJ, Schulze TG, et al. (2015). Kraepelin revisited: schizophrenia from degeneration to failed regeneration. *Mol Psychiatry* 20(6): 671–676.
- Fineberg AM, Ellman LM, Buka S, et al. (2013). Decreased birthweight in psychosis: influence of prenatal exposure to serologically determined influenza and hypoxia. *Schizophr Bull* 39: 1037–1044.
- Franzen G, Ingvar DH (1975). Absence of activation in frontal structures during psychological testing of chronic schizophrenics. *Neurol Neurosurg Psychiatry* 38: 1027–1032.
- Hajima SV, van Haren N, Cahn W, et al. (2013). Brain volumes in schizophrenia: a meta-analysis in over 18,000 subjects. *Schizophr Bull* 39(5): 1129–1138.
- Huber G (1957). Die coenästhetische Schizophrenie. *Fortschr Neurol Psychiatr* 25: 491–520.
- Johnstone EC, Crow TJ, Frith CD, Kreel L (1976). Cerebral ventricular size and cognitive impairment in chronic schizophrenia. *Lancet* 2: 924–926.
- Marsman A, van den Heuvel MP, Klomp DW, et al. (2013). Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. *Schizophr Bull* 39(1): 120–129.
- Mednick SA, Schulsinger F (1973). Studies of children at high risk for schizophrenia. In: Dean SR (ed.). *Schizophrenia*. New York: MSS Information Corp., pp. 247–293.
- PGC – Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014). Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511(7510): 421–427.
- Rüsch N, Tebartz van Elst L, Valerius G, et al. (2008). Neurochemical and structural correlates of executive dysfunction in schizophrenia. *Schizophr Res* 99: 155–163.
- Schnack HG, van Haren NE, Nieuwenhuis M, et al. (2016). Accelerated brain aging in schizophrenia: a longitudinal pattern recognition study. *Am J Psychiatry* 173(6): 607–616.
- Schür RR, Draisma LW, Wijnen JP, et al. (2016). Brain GABA levels across psychiatric disorders: a systematic literature review and meta-analysis of 1H-MRS studies. *Hum Brain Mapp* 37(9): 3337–3352.
- Sekar A, Bialas AR, de Rivera H (2016). Schizophrenia risk from complex variation of complement component 4. *Nature* 530(7589): 177–183.
- Tamminga CA, Lahti RA (1995). Antipsychotic Wirkmechanismen der Neuroleptika bei Schizophrenie: Spekulative Betrachtungen. In: Gerlach (Hrsg.). *Schizophrenie: Dopaminrezeptoren und Neuroleptika*. Berlin, Heidelberg, New York: Springer, S. 185–197.
- van Kesteren CF, Gremmels H, de Witte LD, et al. (2017). Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. *Transl Psychiatry* 7(3): e1075.
- Walton E, Hibar DP, van Erp TG, et al. (2017). Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium. *Acta Psychiatr Scand* 135(5): 439–447.
- Walton E, Hibar DP, van Erp TG, et al. (2018). Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium. *Psychol Med* 48(1): 82–94.
- Ätiologie und Pathogenese: Psychosoziale Faktoren
- Olbrich R (1994). Die Suche nach Risikofaktoren für psychotische Rezidive schizophrener Kranker. Überblicksarbit. *Z Klin Psychol* 23: 153–162.
- APA – American Psychiatric Association (1994). *Diagnostic and Statistical Manual of Mental Disorders: DSM-5*, 4th ed. Washington, DC: American Psychiatric Association.
- Dilling H, Mombour W, Schmidt MH (Hrsg.) (1991). *Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V (F)*. Göttingen, Bern, Toronto: Huber.
- Fusar-Poli P, Borgwardt S, Bechdolf A, et al. (2013). The psychosis high-risk state: a comprehensive state-of-the-art review. *JAMA Psychiatry* 70(1): 107–120.
- Spitzer RL, Endicott J, Robins E (1978). Research diagnostic criteria: rationale and reliability. *Arch Gen Psychiatry* 35: 773–782.
- Verlauf und Ausgang
- Bleuler E (1983). *Lehrbuch der Psychiatrie*. 15. A. Heidelberg: Springer.
- Bleuler M (1972). *Die schizophrenen Geistesstörungen im Lichte langjähriger Kranken- und Familiengeschichten*. Stuttgart, New York: Thieme.
- Ciompi L, Müller C (1976). *Lebensweg und Alter der Schizophrenen. Eine katomnestische Langzeitstudie bis ins Senium*. Berlin, Heidelberg, New York: Springer.
- Häfner H, Riecher-Rössler A, Maurer K, et al. (1992). First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences. *Eur Arch Psychiatry Clin Neurosci* 242: 109–118.
- Herz MI, Lamberti JS, Mintz J, et al. (2000). A program for relapse prevention in schizophrenia: a controlled study. *Arch Gen Psychiatry* 57: 277–283.
- Huber G (1994). *Psychiatrie*. 5. A. Stuttgart: Schattauer.
- Huber G, Gross G, Schüttler R (1979). *Schizophrenie. Eine verlaufs- und soziopsychiatrische Langzeitstudie*. Berlin, Heidelberg, New York: Springer.
- Jablensky A (1995). *Schizophrenia: The epidemiological horizon*. In: Hirsch SR, Weinberger DR (eds.). *Schizophrenia*. Oxford: Blackwell, pp. 206–252.
- Jääskeläinen E, Juola P, Hirvonen N, et al. (2013). A systematic review and meta-analysis of recovery in schizophrenia. *Schizophr Bull* 39(6): 1296–1306.

- Liberman RP, Kopelowicz A (2005). Recovery from schizophrenia: a concept in search of research. *Psychiatr Serv* 56: 735–742.
- Robinson DG, Woerner MG, McMeniman M, et al. (2004). Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. *Am J Psychiatry* 161: 473–479.
- WHO – World Health Organization (1975). Schizophrenia: the International Pilot Study of Schizophrenia. Vol. 1. Geneva: World Health Organization.
- Behandlung: Psychopharmako- und Elektrokonvulsionstherapie*
- Allison DB, Mentore JL, Heo M, et al. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. *Am J Psychiatry* 156: 1686–1696.
- Andreasen NC, Liu D, Ziebell S, et al. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. *Am J Psychiatry* 170(6): 609–615.
- Barbui C, Saraceno B, Liberati A, Garattini S (1996). Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials. *Eur Psychiatry* 11: 306–311.
- Beasley CM, Dellva MA, Tamura RN, et al. (1999). Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. *Br J Psychiatry* 174: 23–30.
- Bymaster FP, Calligaro DO, Falcone JF, et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. *Neuropsychopharmacology* 14: 87–96.
- Casey DE (1997). Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia? *Int Clin Psychopharmacol* 12 (Suppl 1): S19–S27.
- Chakos M, Lieberman J, Hoffman E, et al. (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. *Am J Psychiatry* 158: 518–526.
- Cole JO (1964). Phenothiazine treatment in acute schizophrenia. *Arch Gen Psychiatry* 10: 246–261.
- Conley RR, Ascher-Svanum H, Zhu B, et al. (2007). The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. *Schizophr Res* 90(1–3): 186–197.
- Correll CU, Schenk EM (2008). Tardive dyskinesia and new antipsychotics. *Curr Opin Psychiatr* 21: 151–156.
- Correll CU, Rummel-Kluge C, Corves C, et al. (2009). Antipsychotic combinations vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. *Schizophr Bull* 35: 443–457.
- Correll CU, Rubio JM, Inczedy-Farkas G, et al. (2017). Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. *JAMA Psychiatry* 74(7): 675–684.
- Csernansky JG, Mahmoud R, Brenner R (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. *N Engl J Med* 346: 16–22.
- Davis JM, Barter JT, Kane JM (1989). Antipsychotic drugs. In: Kaplan HJ, Sadock BJ (eds.). Comprehensive Textbook of Psychiatry. Baltimore: Williams and Wilkins, pp. 1591–1626.
- Davis JM, Mentalon L, Watanabe MD (1994). Depot antipsychotic drugs. Place in therapy. *Drugs* 47: 741–773.
- Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. *Arch Gen Psychiatry* 60: 553–564.
- de Oliveira IR, de Sena EP, Pereira EL, et al. (1996). Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis. *J Clin Pharm Ther* 21: 229–236.
- DGPPN – Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (1998). PraxisLeitlinien in Psychiatrie und Psychotherapie. Band 1: Schizophrenie. Darmstadt: Steinkopff.
- Gaebel W (1994). Intermittent medication – an alternative? *Acta Psychiatr Scand* 89: 33–38.
- Gaebel W, Awad AG (1994). Prediction of Neuroleptic Treatment Outcome in Schizophrenia. Concepts and methods. Wien: Springer.
- Gaebel W, Falkai P, Weinmann S, Wobrock T (2006). Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff.
- Galling B, Roldán A, Hagi K, et al. (2017). Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. *World Psychiatry* 16(1): 77–89.
- Gardner DM, Murphy AL, O'Donnell H, et al. (2010). International consensus study of antipsychotic dosing. *Am J Psychiatry* 167(6): 686–693.
- Haase H-J (1954). Über Vorkommen und Deutung des psychomotorischen Parkinsonsyndroms bei Megaphen- bzw. Largactil-Dauerbehandlung. *Nervenarzt* 15: 70–74.
- Helfer B, Samara MT, Huhn M, et al. (2016). Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. *Am J Psychiatry* 173(9): 876–886.
- Ho BC, Andreasen NC, Ziebell S, et al. (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. *Arch Gen Psychiatry* 68(2): 128–137.
- Hyttel J, Arndt J, van den Berghe M (1989). Selective dopamine D₁ and D₂ receptor antagonists. In: Dahl SG, Gram LF (eds.). Clinical Pharmacology in Psychiatry. Berlin, Heidelberg, New York: Springer, pp. 109–122.
- Jones PB, Barnes TRE, Davies L, et al. (2006). Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia – cost utility of the latest antipsychotic drugs in schizophrenia study (CUTLASS 1). *Arch Gen Psychiatry* 63: 1079–1086.
- Kahn RS, Fleischhacker WW, et al. for the EUFEST study group (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizoaffective disorder: an open randomised clinical trial. *Lancet* 371: 1085–1097.
- Kane JM, Marder SR (1993). Psychopharmacologic treatment of schizophrenia. *Schizophr Bull* 19: 287–302.
- Kane JM, Aguglia E, Altamura AC, et al. (1998). Guidelines for depot antipsychotic treatment in schizophrenia. *Eur Neuropsychopharmacol* 8: 55–66.
- Kinon BJ, Kane JM, Johns C, et al. (1993). Treatment of neuroleptic-resistant schizophrenic relapse. *Psychopharmacol Bull* 29: 309–314.
- Kishimoto T (2012). New results alter balance of evidence of meta-analysis on long-acting injectable vs. oral antipsychotics in schizophrenia. *Schizophr Res* 136 (Suppl 1): S4–S5.
- Kishimoto T, Agarwal V, Kishi T, et al. (2013a). Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. *Mol Psychiatry* 18(1): 53–66.
- Kishimoto T, Nitta M, Borenstein M, et al. (2013b). Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. *J Clin Psychiatry* 74(10): 957–965.
- Kissling W, Kane JM, Barnes TR, et al. (1991). Guidelines for neuroleptic relapse prevention in schizophrenia: Towards a consensus view. In: Kissling W (ed.). Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Heidelberg, Berlin: Springer, pp. 155–163.
- Leucht S (2007). Therapie der Schizophrenie. Evidenzbasierte Behandlung. München: Elsevier Urban & Fischer.
- Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. *Schizophr Res* 35: 51–68.
- Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002). Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. *Am J Psychiatry* 159: 180–190.
- Leucht S, Wahlbeck K, Hamann J, Kissling W (2003). New generation antipsychotics versus low-potency conventional antipsychotics. A systematic review and meta-analysis. *Lancet* 361: 1581–1589.
- Leucht S, Corves C, Arbter D, et al. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 373: 31–41.
- Leucht S, Heres S, Kissling W, Davis J (2011a). Evidence-based pharmacotherapy of schizophrenia. *Int J Neuropsychopharmacol* 14(2): 269–284.

362.e4 10 Schizophrenien und andere psychotische Störungen

- Leucht C, Heres S, Kane JM, et al. (2011b). Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. *Schizophr Res* 127(1–3): 83–92.
- Leucht S, Tardy M, Komossa K, et al. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. *Lancet* 379(9831): 2063–2071.
- Leucht S, Cipriani A, Spinelli L, et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet* 382(9896): 951–962.
- Leucht S, Samara M, Heres S, et al. (2014). Dose equivalents for second-generation antipsychotics: the minimum effective dose method. *Schizophr Bull* 40(2): 314–326.
- Leucht S, Samara M, Heres S, et al. (2015). Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. *Schizophr Bull* 41(6): 1397–1402.
- Leucht S, Samara M, Heres S, Davis JM (2016). Dose equivalents for antipsychotic drugs: the DDD method. *Schizophr Bull* 42 (Suppl 1): S90–94.
- Lieberman JA, Stroup TS, McEvoy JP, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 353: 1209–1223.
- Marshall M, Lewis S, Lockwood A, et al. (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. *Arch Gen Psychiatry* 62(9): 975–983.
- McEvoy JP, Hogarty GE (1991). Optimal dose of neuroleptic in acute schizophrenia. *Arch Gen Psychiatry* 48: 740–745.
- Meduna LJ (1935). Die Konvulsionstherapie der Schizophrenie. *Psychiatr Neurol Wschr* 37: 317–319.
- Naber D, Lambert M, Krausz M (1999). Atypische Antipsychotika in der Behandlung schizophrener Patienten. Bremen: uni-med.
- Németh G, Laszlovszky I, Czobor P, et al. (2017). Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. *Lancet* 389(10074): 1103–1113.
- Petrides G, Malur C, Braga RJ, et al. (2015). Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. *Am J Psychiatry* 172(1): 52–58.
- Robinson D, Woerner MG, Alvir JM, et al. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry* 56: 241–247.
- Samara MT, Leucht C, Leeflang MM, et al. (2015). Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. *Am J Psychiatry* 172(7): 617–629.
- Samara MT, Dold M, Gianatsis M, et al. (2016). Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. *JAMA Psychiatry* 73(3): 199–210.
- Schotte A, Janssen PF, Gommeren W, et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. *Psychopharmacol* 124: 57–73.
- Seeman P (2002). Atypical antipsychotics: mechanism of action. *Can J Psychiatry* 47(1): 27–38.
- Sernyak MJ, Leslie DL, Alarcon RD, et al. (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. *Am J Psychiatry* 159: 561–566.
- Shepherd M, Watt D, Falloon I, Smeeton N (1989). The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. *Psychol Med Suppl* 15: 1–46.
- Siris SG (1991). Diagnosis of secondary depression in schizophrenia: implications for DSM-5. *Schizophr Bull* 17: 75–98.
- Siskind D, McCartney L, Goldschlager R, Kisely S (2016). Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. *Br J Psychiatry* 209(5): 385–392.
- Takeuchi H, Thiyanavadiel S, Agid O, Remington G (2017). Rapid vs. slow antipsychotic initiation in schizophrenia: a systematic review and meta-analysis. *Schizophr Res* 193: 29–36.
- Wunderink L, Nienhuis FJ, Sytema S, et al. (2007). Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. *J Clin Psychiatry* 68(5): 654–661.
- Wunderink L, Nieboer RM, Wiersma D, et al. (2013). Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. *JAMA Psychiatry* 70(9): 913–920.
- Zheng W, Xiang YT, Xiang YQ, et al. (2016). Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. *Acta Psychiatr Scand* 134(5): 385–398.
- Zohar J, Stahl S, Moller HJ, et al. (2015). A review of the current nomenclature for psychotropic agents and an introduction to the neuroscience-based nomenclature. *Eur Neuropsychopharmacol* 25(12): 2318–2325.
- Behandlung: *Psycho- und Soziotherapie*
- Aguilar EJ, Corripio I, García-Martí G, et al. (2018). Emotional fMRI auditory paradigm demonstrates normalization of limbic hyperactivity after cognitive behavior therapy for auditory hallucinations. *Schizophr Res* 193: 304–312.
- Alvarez-Jimenez M, Parker AG, Hetrick SE, et al. (2011). Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. *Schizophr Bull* 37(3): 619–630.
- Barbui C, Signoretti A, Mule S, Boso M, et al. (2009). Does the addition of a second antipsychotic drug improve clozapine treatment? *Schizophr Bull* 35: 458–468.
- Barlati S, Deste G, de Peri L, et al. (2013). Cognitive remediation in schizophrenia: current status and future perspectives. *Schizophr Res Treatment* 2013: 156084.
- Bechdolf A, Klingberg S (2014). Psychotherapie bei schizophrenen Störungen: kein Evidenz-, sondern ein Implementierungsproblem. *Psychiatr Prax* 41(1): 8–10; www.ddpp.eu/files/ddpp/pdf/Freie%20Texte/Bechdolf,%20Klingberg%20%20Psychotherapie%20bei%20schizophrenen%20Stoerungen.pdf (letzter Zugriff: 11.5.2018).
- Bell M, Tsang HW, Greig TC, Bryson GJ (2009). Neurocognition, social cognition, perceived social discomfort, and vocational outcomes in schizophrenia. *Schizophr Bull* 35(4): 738–747.
- Bilder RM, Bogerts B, Ashtari M, et al. (1995). Anterior hippocampal volume reductions predict 'frontal lobe' dysfunction in first episode schizophrenia. *Schizophr Res* 17: 58.
- Bohlken MM, Hugdahl K, Sommer IE (2017). Auditory verbal hallucinations: neuroimaging and treatment. *Psychol Med* 47(2): 199–208.
- Burkhardt E, Leopold K, Laier S, et al. (2017). Was tun, bevor es losgeht? FRITZ – Das Frühinterventions- und Therapiezentrum in Berlin. *Z Psychiatr Psych PS* 65: 105–112.
- Cavelti M, Kvrgic S, Beck EM, et al. (2012). Self-stigma and its relationship with insight, demoralization, and clinical outcome among people with schizophrenia spectrum disorders. *Compr Psychiatry* 53(5): 468–479.
- Cella M, Wykes T (2017). The nuts and bolts of cognitive remediation: exploring how different training components relate to cognitive and functional gains. *Schizophr Res* 2017 Sep 14, pii: S0920-9964(17)30571-6.
- Coursey RD (1989). Psychotherapy with persons suffering from schizophrenia: the need for a new agenda. *Schizophr Bull* 15: 349–353.
- de Maat S, de Jonghe F, Schoevers R, Dekker J (2009). The effectiveness of long-term psychoanalytic therapy: a systematic review of empirical studies. *Harv Rev Psychiatry* 17(1): 1–23.
- Dold J, Droews L, Vauth R (2017). Evidenzbasierte Interventionen in der frühen Entwicklungsphase schizophrener Störungen. *Z Psychiatr Psych PS* 65: 113–120.
- Eckman TA, Wirshing WC, Marder SR, et al. (1992). Technique for training schizophrenic patients in illness self-management: a controlled trial. *Am J Psychiatry* 149: 1549–1555.
- Freeman D, Dunn G, Startup H, et al. (2015). A parallel, single-blind, randomised controlled trial (N = 150) with a mediation analysis. *Lancet Psychiatry* 2(4): 305–313.
- Gaebel W, Falkai P, Weinmann S, Wobrock T (2006). *Behandlungsleitlinie Schizophrenie*. Darmstadt: Steinkopff.

- Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? *Schizophr Bull* 26: 119–136.
- Hahlweg K, Dürr H, Müller U et al. (1995). Familienbetreuung schizophrener Patienten. Ein verhaltenstherapeutischer Ansatz zur Rückfallprophylaxe. Konzepte, Behandlungsanleitung und Materialien. Weinheim: PVU.
- Heaton R, Paulsen JS, McAdams LA, et al. (1994). Neuropsychological deficits in schizophrenics: relationship to age, chronicity, and dementia. *Arch Gen Psychiatry* 51: 469–476.
- Heinssen RK, Liberman RP, Kopelowicz A (2000). Psychosocial skills training for schizophrenia: lessons from the laboratory. *Schizophr Bull* 26: 21–46.
- Hutton P, Taylor PJ (2014). Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. *Psychol Med* 44(3): 449–468.
- Jauhar S, McKenna PJ, Radua J, et al. (2014). Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. *Br J Psychiatry* 204(1): 20–29.
- Jolley S, Browning S, Corrigall R, et al. (2017). Coping with unusual experiences for 12–18 year olds (CUES+): a transdiagnostic randomised controlled trial of the effectiveness of cognitive therapy in reducing distress associated with unusual experiences in adolescent mental health services: study protocol for a randomised controlled trial. *Trials* 18(1): 586.
- Kates J, Rockland LH (1994). Supportive psychotherapy of the schizophrenic patient. *Am J Psychother* 48: 543–561.
- Keefe RS, Harvey PD (2012). Cognitive impairment in schizophrenia. *Handb Exp Pharmacol* 213: 11–37.
- Kurtz MM, Mueser KT (2008). A meta-analysis of controlled research on social skills training for schizophrenia. *J Consult Clin Psychol* 76(3): 491–504.
- Lencer RH, Weiden MSH, Stieglitz R-D, Vauth R (eds.) (2011). When Psychopharmacology is not Enough: Using Cognitive Behavioral Therapy Techniques for Persons with Persistent Psychosis. Göttingen: Hogrefe.
- Lincoln TM, Wilhelm K, Nestoruc Y (2007). Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. *Schizophr Res* 96(1–3): 232–245.
- Lonergan A (2017). The meaning of voices in understanding and treating psychosis: moving towards intervention informed by collaborative formulation. *Eur J Psychol* 13(2): 352–365.
- McGurk SR, Twamley EW, Sitzer DI, et al. (2007). A meta-analysis of cognitive remediation in schizophrenia. *Am J Psychiatry* 164: 1791–1802.
- Morrison AP, Bentall RP, French P, et al. (2002). Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. *Br J Psychiatry* (Suppl 43): 75–84.
- Mueser KT, Deavers F, Penn DL, Cassisi JE (2013). Psychosocial treatments for schizophrenia. *Annu Rev Clin Psychol* 9: 465–497.
- Nuechterlein KH, Dawson ME, Gitlin M, et al. (1992). Developmental processes in schizophrenic disorders: longitudinal studies of vulnerability and stress. *Schizophr Bull* 18: 387–425.
- Nuechterlein KH, Subotnik KL, Ventura J, et al. (2012). The puzzle of schizophrenia: tracking the core role of cognitive deficits. *Dev Psychopathol* 24(02): 529–536.
- Palmer BW, Heaton RK, Paulsen JS (1997). Is it possible to be schizophrenic and neuropsychologically normal? *Neuropsychol* 11: 437–447.
- Penn DL, Waldheter EJ, Perkins DO, et al. (2005). Psychosocial treatment for first-episode psychosis: a research update. *Am J Psychiatry* 162: 2220–2232.
- Roder V, Mueller DR, Schmidt SJ (2011). Effectiveness of integrated psychological therapy (IPT) for schizophrenia patients: a research update. *Schizophr Bull* 37 (Suppl 2): S71–79.
- Surmann M, Gruchalla LV, Falke S, et al. (2017). The importance of strengthening competence and control beliefs in patients with psychosis to reduce treatment hindering self-stigmatization. *Psychiatry Res* 255: 314–320.
- Tarrier N (1992). Management and modification of residual positive symptoms. In: Birchwood M, Tarrier N (eds.). *Elevations in the Psychological Management of Schizophrenia*. New York: Wiley, pp. 147–169.
- Turner DT, McGlanaghy E, Cuijpers P, et al. (2018). A meta-analysis of social skills training and related interventions for psychosis. *Schizophr Bull* 44(3):475–491.
- van der Gaag M, Valmaggia LR, Smit F (2014). The effects of individually tailored formulation-based cognitive behavioural therapy in auditory hallucinations and delusions: a meta-analysis. *Schizophr Res* 156: 30–37.
- van der Gaag M, van den Berg D, Ising H (2017). CBT in the prevention of psychosis and other severe mental disorders in patients with an at risk mental state: a review and proposed next steps. *Schizophr Res* 7 Aug 28. pii: S0920-9964(17)30494-2 [Epub ahead of print].
- Vauth R (2004a). Kriseninterventionsstrategien bei psychotischen Störungen. In: Riecher-Rössler A, Berger P, Yilmaz T, Stieglitz R-D (Hrsg.). *Psychiatrisch-psychotherapeutische Krisenintervention*. Göttingen: Hogrefe, S. 219–234.
- Vauth R (2004b). Psychotherapie bei schizophrenen Störungen auf der Grundlage modernen Case Managements. In: Falkai P, Pajonk F-G (Hrsg.). *Langzeittherapie der Schizophrenie*. Bremen: unimed, S. 84–97.
- Vauth R (2007). Die umfassende Bedeutung schizophrener Störungen als klinische Herausforderung. In: Strauß B, Hohagen F, Caspar F (Hrsg.). *Lehrbuch Psychotherapie*. Teilband 1. Göttingen: Hogrefe, S. 611–644.
- Vauth R (2010). Training of emotional intelligence in schizophrenia. In: Röder V, Medalia A (eds.). *Understanding and Treating Neuro- and Social Cognition in Schizophrenia Patients*. Basel: Karger, pp. 79–85.
- Vauth R (2011). Wenn Antipsychotika nicht helfen – Kognitiv-verhaltenstherapeutische Interventionen bei persistierendem Wahn und chronischen Stimmenhören. *Nervenheilkunde* 30 (Themenband Schizophrenie 4).
- Vauth R, Stieglitz R-D (2007). Chronisches Stimmenhören und persistierender Wahn. *Fortschritte der Psychotherapie*. Göttingen: Hogrefe.
- Vauth R, Stieglitz R-D (2008). *Training Emotionaler Intelligenz bei schizophrenen Störungen*. Ein Therapiemanual. Göttingen: Hogrefe.
- Vauth R, Stieglitz R-D (2017). Behandlungsbereitschaft bei Menschen mit schizophrenen Störungen nachhaltig aufbauen. Ein Mehrebenen-Modell zur Interventionsplanung. *Z Psychiatr Psych PS* 65(2): 73–82.
- Vauth R, Kleim B, Wirtz M, Corrigan PW (2007). Self-efficacy and empowerment as outcomes of self-stigmatizing and coping in schizophrenia. *Psychiatry Res* 150: 71–80.
- Wiedl KH (1999). Rehab rounds: cognitive modifiability as a measure of readiness for rehabilitation. *Psychiatr Serv* 50(11): 1411–1413.

10.2 ANDERE PSYCHOTISCHE STÖRUNGEN

Übersicht: Klassifikation, schizotypale Störungen, induzierte wahnhafte Störungen

- Bleuler E (1911). *Dementia praecox oder die Gruppe der Schizophrenien*. Leipzig: Deuticke.
- Jablensky A (2001). Classification of nonschizophrenic psychotic disorders: a historical perspective. *Curr Psychiatry Rep* 3: 326–331.
- Kraepelin E (1899). *Psychiatrie. Ein Lehrbuch für Studierende und Ärzte*. 6. A. Leipzig: Barth.
- Schneider K (1950). *Klinische Psychopathologie*. 3. A. Stuttgart: Thieme.
- Silveira JM, Seeman MV (1995). Shared psychotic disorder: a critical review of the literature. *Can J Psychiatry* 40: 389–395.
- Anhaltende wahnhafte Störungen*
- Freud S (1911). Psychoanalytische Bemerkungen über einen autobiografisch beschriebenen Fall von Paranoia. In: *Jahrbuch für psychoanalytische und psychopathologische Forschungen*. III, 1. Hälfte, Leipzig: Deuticke.
- Gaupp R (1914). Zur Psychologie des Massenmordes. Hauptlehrer Wagner aus Degerloch. Eine kriminopsychologische und psychiatrische Studie In: Gruhle HW, Wetzel A (Hrsg.). *Verbrechertypen*. Berlin: Springer, 1. Band 1, Heft 3.
- Ibáñez-Casas I, Cervilla JA (2012). Neuropsychological research in delusional disorder: a comprehensive review. *Psychopathology* 45: 78–95.
- Jäger M, Bottlender R, Strauß A, Möller HJ (2004). Klassifikation der funktionalen Psychosen. Die Bedeutung der ICD-10-Diagnosen (Forschungskriterien) für die Vorhersage des Langzeitverlaufes. *Fortschr Neurol Psychiat* 72: 70–78.

362.e6 10 Schizophrenien und andere psychotische Störungen

- Jaspers K (1913). Allgemeine Psychopathologie. Berlin: Springer.
- Kretschmer E (1918). Der sensitive Beziehungswahn. Ein Beitrag zur Paranoiafrage und zur psychiatrischen Charakterlehre. Berlin: Springer.
- Leonhard K (1948). Grundlagen der Psychiatrie. Stuttgart: Enke.
- Manschreck TC, Khan NL (2006). Recent advantages in the treatment of delusional disorder. *Can J Psychiatry* 51: 114–119.
- Silva H, Jerez S, Ramirez A, et al. (1998). Effects of pimozide on the psychopathology of delusional disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 22: 331–340.
- Voderholzer U (2014). Wahnhafte und schizoaffective Störungen (ICD-10 F22 bzw. F25). In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen. State of the Art. 11. A., München: Elsevier Urban & Fischer, S. 159–168.
- Akute vorübergehende Störungen*
- Castagnini AC, Fusar-Poli P (2017). Diagnostic validity of ICD-10 acute and transient psychotic disorders and DSM-5 brief psychotic disorder. *Eur Psychiatry* 45: 104–113.
- Castagnini A, Foldager L, Bertelsen A (2013a). Long-term stability of acute and transient psychotic disorders. *Aust N Z J Psychiatry* 47: 59–64.
- Castagnini A, Foldager L, Bertelsen A (2013b). Excess mortality of acute and transient psychotic disorders: comparison with bipolar affective disorder and schizophrenia. *Acta Psychiatr Scand* 128: 370–375.
- Esan O, Fawole OI (2014). Acute and transient psychotic disorder in a developing country. *Int J Soc Psychiatry* 60: 442–448.
- Jäger M, Riedel M, Möller HJ (2007). Akute vorübergehende psychotische Störungen (ICD-10: F23) – Empirische Befunde und Implikationen für die Therapie. *Nervenarzt* 78: 745–752.
- Jorgensen P, Bennedsen B, Christensen J, Hyllested A (1997). Acute and transient psychotic disorder: a 1-year follow-up study. *Acta Psychiatr Scand* 96: 150–154.
- Langfeldt G (1939). The Schizophreniform States. Copenhagen: Munksgaard.
- Leonhard K (1948). Grundlagen der Psychiatrie. Stuttgart: Enke.
- Pillmann F, Marneros A (2005). Longitudinal follow-up of acute and transient psychotic disorders and schizophrenia. *Br J Psychiatry* 187: 286–287.
- Strömgren E (1987). The development of the concept of reactive psychoses. *Psychopathology* 20: 62–67.
- Wimmer A (1916). Psykogene Sindssygdomsformer. In: Wimmer A. (ed.). St. HansHospital 1816–1915. Jubilaeumsskrift, Kobenhavn: GEC Grad Publishers, S. 85–216.
- Schizoaffective Störungen*
- Angst J, Scharfetter C, Stassen HH (1993). Classification of schizoaffective patients by multidimensional scaling and cluster analysis. *Psychiatria Clin* 16: 254–264.
- Baethge C (2003). Long-term treatment of schizoaffective disorder. Review and recommendations. *Pharmacopsychiatry* 36: 45–56.
- Brockington IF, Kendell RE, Winwright S, et al. (1979). The distinction between affective psychoses and schizophrenia. *Br J Psychiatry* 135: 243–248.
- Heslin M, Lomans B, Lappin JM, et al. (2015). Diagnostic change 10 years after a first episode of psychosis. *Psychol Med* 45: 2757–2769.
- Jäger M, Becker T, Weinmann S, Frasch K (2010). Treatment of schizoaffective disorder – a challenge for evidence-based psychiatry. *Acta Psychiatr Scand* 121: 22–32.
- Jäger M, Becker T, Haack S, Frasch K (2011). Schizoaffective disorder – an ongoing challenge for psychiatric nosology. *Eur Psychiatry* 26: 159–165.
- Kasanin J (1933). The acute schizoaffective psychoses. *Am J Psychiatry* 13: 97–126.
- Levinson DF, Umapathy C, Musthaq M (1999). Treatment of schizoaffective disorder and schizophrenia with mood symptoms. *Am J Psychiatry* 156: 1138–1148.
- Marneros A, Deister A, Rhode A (1990). Psychopathological and social status of patients with affective, schizophrenic and schizoaffective disorders after long-term course. *Acta Psychiatr Scand* 82: 352–358.
- Murru A, Hidalgo D, Bernardo M, et al. (2015). Antipsychotic switching in schizoaffective disorder: a systematic review. *World J Biol Psychiatry* 9: 1–19.
- Psychische Störungen im Wochenbett*
- Brockington IF (2004). Diagnosis and management of post-partum disorders: a review. *World Psychiatry* 3: 89–95.
- Fallgatter AJ, Schnizlein M, Pfuhlmann B, Heidrich A (2002). Klinische Aspekte der Wochenbettpsychosen. Übersicht mit drei Fallbeispielen. *Nervenarzt* 73: 680–685.
- Lanczik M, Fritze J, Beckmann H (1990). Puerperal and cycloid psychoses: results of a retrospective study. *Psychopathology* 23: 220–227.
- Rhode A, Marneros A (1993). Postpartum psychoses: onset and long-term outcome. *Psychopathology* 26: 203–209.
- Riecher-Rössler A, Rhode A (2005). Perinatal Stress, Mood and Anxiety Disorders. From Bench to Bedside. Basel: Karger.
- LEITLINIEN (SYSTEMATISCH EVIDENZBASIERT)**
- AWMF-S1-Leitlinie Schizophrenie, schizotyp und wahnhafte Störungen (F2). Registrierungsnummer 028–003.
- AWMF-S3-Leitlinie Schizophrenie. Registrierungsnummer 038–009.
- Gaebel W, Falkai P, Weinmann S, Wobrock T (2006). Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff.
- Lehman AF, Lieberman JA, Dixon LB, et al. (2004). Practice guideline for the treatment of patients with schizophrenia. 2nd ed. *Am J Psychiatry* 161(2): 1–56.
- SYSTEMATISCHE COCHRANE REVIEWS* (WWW.COCHRANE.DE/DEUTSCH)**
- Adams CE, Bergman H, Irving CB, Lawrie S (2013). Haloperidol versus placebo for schizophrenia. *Cochrane Database Syst Rev* 11: CD003082.
- Adams CE, Awad GA, Rathbone J, et al. (2014). Chlorpromazine versus placebo for schizophrenia. *Cochrane Database Syst Rev* 1: CD000284.
- Almerie MQ, Okba Al Marhi M, et al. (2015). Social skills programmes for schizophrenia. *Cochrane Database Sys Rev* 6: CD009006.
- Babalola O, Gormez V, Alwan NA, et al. (2014). Length of hospitalisation for people with severe mental illness. *Cochrane Database Syst Rev* 1: CD000384.
- Bergman H, Soares-Weiser K (2018). Anticholinergic medication for antipsychotic-induced tardive dyskinesia. *Cochrane Database Syst Rev* 1: CD000204.
- Bergman H, Rathbone J, Agarwal V, Soares-Weiser K (2018a). Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. *Cochrane Database Syst Rev* 2: CD000459.
- Bergman H, Bhoopathi PS, Soares-Weiser K (2018b). Benzodiazepines for antipsychotic-induced tardive dyskinesia. *Cochrane Database Syst Rev* 1: CD000205.
- Buckley LA, Maayan N, Soares-Weiser K, Adams CE (2015). Supportive therapy for schizophrenia. *Cochrane Database Syst Rev* 4: CD004716.
- Catty J, Bunstead Z, Burns T, Camas A (2007). Day centres for severe mental illness. *Cochrane Database Syst Rev* 1: CD001710.
- Chilvers R, MacDonald GM, Hayes AA (2006). Supported housing for people with severe mental disorders. *Cochrane Database Syst Rev* 4: CD000453.
- Dieterich M, Irving CB, Bergman H, et al. (2017). Intensive case management for severe mental illness. *Cochrane Database Syst Rev* 1: CD007906.
- Dold M, Li C, Tardy M, et al. (2012). Benzodiazepines for schizophrenia. *Cochrane Database Syst Rev* 11: CD006391.
- Donnelly L, Rathbone J, Adams CE (2013). Haloperidol dose for the acute phase of schizophrenia. *Cochrane Database Syst Rev* 8: CD001951.
- El-Sayeh HG, Morganti C (2006). Aripiprazole for schizophrenia. *Cochrane Database Syst Rev* 2: CD004578.
- El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H (2018). Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. *Cochrane Database Syst Rev* 1: CD000458.
- Essali A, Al-Haj Haasan N, Li C, Rathbone J (2009). Clozapine versus typical neuroleptic medication for schizophrenia. *Cochrane Database Syst Rev* 1: CD000059.
- Essali A, Soares-Weiser K, Bergman H, Adams CE (2018). Calcium channel blockers for antipsychotic-induced tardive dyskinesia. *Cochrane Database Syst Rev* 3: CD000206.

- Faulkner G, Cohn T, Remington G (2007). Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 1: CD005148.
- Jones C, Hacker D, Cormac I, et al. (2012). Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database Syst Rev 4: CD008712.
- Leucht S, Tardy M, Komossa K, et al. (2012). Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 5: CD008016.
- Leucht S, Helfer B, Dold M, et al. (2014). Carbamazepine for schizophrenia. Cochrane Database Syst Rev 5: CD001258.
- Leucht S, Helfer B, Dold M, et al. (2015). Lithium for schizophrenia. Cochrane Database Syst Rev 10: CD003834.
- Malmborg L, Fenton M (2001). Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness. Cochrane Database Syst Rev 3: CD001360.
- Morriss R, Vinjamuri I, Faizal MA, et al. (2013). Training to recognise the early signs of recurrence in schizophrenia. Cochrane Database Syst Rev 2: CD005147.
- Mota Neto JIS, Lima MS, Soares BGO (2002). Amisulpride for schizophrenia. Cochrane Database Syst Rev 2: CD001357.
- Mothi M, Sampson S (2013). Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev 11: CD001949.
- Murphy SM, Irving CB, Adams CE, Waqar M (2015). Crisis intervention for people with severe mental illnesses. Cochrane Database Syst Rev 1: CD001087.
- Ostinelli EG, Brooke-Powney MJ, Li X, Adams CE (2017). Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 7: CD009377.
- Pharoah F, Mari J, Rathbone J, Wong W (2010). Family intervention for schizophrenia. Cochrane Database Syst Rev 12: CD000088.
- Premkumar TS, Pick J (2006). Lamotrigine for schizophrenia. Cochrane Database Syst Rev 4: CD005962.
- Resende Lima A, Soares-Weiser K, Bacalchuk J, Barnes TRE (1999). Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 4: CD001950.
- Sampson S, Mansour M, Maayan N, et al. (2013). Intermittent drug techniques for schizophrenia. Cochrane Database Syst Rev 7: CD006196.
- Shek E, Bardhan S, Cheine MV, et al. (2001). Beta-blocker supplementation of standard drug treatment for schizophrenia. Cochrane Database Syst Rev 3: CD000234.
- Shek E, Stein AT, Shansis FM, et al. (2009). Day hospital versus outpatient care for people with schizophrenia. Cochrane Database Syst Rev 4: CD003240.
- Skelton M, Khokhar WA, Thacker SP (2015). Treatments for delusional disorder. Cochrane Database Syst Rev 5: CD009785.
- Soares-Weiser K, Rathbone J, Ogawa Y, et al. (2018a). Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 3: CD000208.
- Soares-Weiser K, Maayan N, Bergman H (2018b). Vitamin E for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 1: CD000209.
- Srisurapanont M, Maneeton B, Maneeton N (2004). Quetiapine for schizophrenia. Cochrane Database Syst Rev 2: CD000967.
- Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H (2008). Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 3: CD000207.
- Tharyan P, Adams CE (2005). Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2: CD000076.
- Wahlbeck K, Cheine M, Essali MA (2009). Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 1: CD000059.
- Wang J, Sampson S (2014). Sulpiride versus placebo for schizophrenia. Cochrane Database Syst Rev 4: CD007811.
- Wang Y, Xia J, Helfer B, et al. (2016). Valproate for schizophrenia. Cochrane Database Syst Rev 11: CD004028.
- Whitehead C, Moss S, Cardno A, Lewis G (2002). Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev 2: CD002305.
- Xia J, Li C (2007). Problem solving skills for schizophrenia. Cochrane Database Syst Rev 2: CD006365.
- Xia J, Merinder LB, Belgamwar MR (2011). Psychoeducation for schizophrenia. Cochrane Database Syst Rev 6: CD002831.

PATIENTENRATGEBER

- Bäuml J (2005). Psychosen aus dem schizophrenen Formenkreis: Ein Ratgeber für Patienten und Angehörige. Heidelberg: Springer.
- Finzen A (2013). Schizophrenie: Die Krankheit verstehen, behandeln, bewältigen. 2. A. Köln: Psychiatrie Verlag.
- Hell D, Schüpbach D (2008). Schizophrenie. Ein Ratgeber für Patienten und Angehörige. 4. A. Heidelberg: Springer.